Twist Bioscience Corp Stock Today
| TWST Stock | USD 39.24 1.53 4.06% |
PerformanceVery Weak
| Odds Of DistressLow
|
Twist Bioscience is selling for under 39.24 as of the 3rd of May 2025; that is 4.06% increase since the beginning of the trading day. The stock's last reported lowest price was 38.45. Twist Bioscience has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of February 2025 and ending today, the 3rd of May 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of October 2018 | Category Healthcare | Classification Health Care |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 59.65 M outstanding shares of which 9.73 M shares are at this time shorted by private and institutional investors with about 7.71 trading days to cover. More on Twist Bioscience Corp
Moving together with Twist Stock
| 0.86 | A | Agilent Technologies | PairCorr |
| 0.73 | VANI | Vivani Medical | PairCorr |
| 0.84 | DNLI | Denali Therapeutics Earnings Call This Week | PairCorr |
Moving against Twist Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Twist Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Emily Leproust | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTwist Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Twist Bioscience's financial leverage. It provides some insight into what part of Twist Bioscience's total assets is financed by creditors.
| |||||
Twist Bioscience Corp (TWST) is traded on NASDAQ Exchange in USA. It is located in 681 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 923 people. Twist Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.34 B. Twist Bioscience Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.65 M outstanding shares of which 9.73 M shares are at this time shorted by private and institutional investors with about 7.71 trading days to cover.
Twist Bioscience Corp currently holds about 504.97 M in cash with (64.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.93.
Check Twist Bioscience Probability Of Bankruptcy
Ownership AllocationThe majority of Twist Bioscience Corp outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Twist Bioscience to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Twist Bioscience Corp. Please pay attention to any change in the institutional holdings of Twist Bioscience Corp as this could imply that something significant has changed or is about to change at the company.
Check Twist Ownership Details
Twist Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-12-31 | 1.4 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.4 M | |
| First Light Asset Management, Llc | 2024-12-31 | 1.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 899.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 895.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 879 K | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 853.7 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 846.1 K | |
| Tao Capital Management Lp | 2024-12-31 | 828.8 K | |
| Artisan Partners Limited Partnership | 2024-12-31 | 5.9 M | |
| Vanguard Group Inc | 2024-12-31 | 5.8 M |
Twist Bioscience Historical Income Statement
Twist Stock Against Markets
Twist Bioscience Corporate Management
| Dennis JD | Chief VP | Profile | |
| William Banyai | GM Development | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Michael Fero | Chief Officer | Profile |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.